Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,126 Mln
P/E Ratio
--
P/B Ratio
0.82
Industry P/E
--
Debt to Equity
0.39
ROE
-0.04 %
ROCE
-2.95 %
Div. Yield
0 %
Book Value
1.97
EPS
-0.08
CFO
$-313.63 Mln
EBITDA
$-598.69 Mln
Net Profit
$-1,512.83 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Opko Health Inc (OPK)
| -3.06 | -20.83 | -5.00 | 15.85 | -22.23 | -6.37 | -20.67 |
|
BSE Sensex
| 1.72 | 3.50 | 4.95 | 8.90 | 11.18 | 21.04 | 11.14 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Opko Health Inc (OPK)
| -2.63 | 20.80 | -74.01 | 21.77 | 168.71 | -51.16 | -38.41 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 133.68 | 11,202.40 | 13.05 | 159.08 | |
| 97.36 | 10,408.27 | 23.02 | 24.54 | |
| 112.63 | 11,495.49 | 3.72 | 110.75 | |
| 159.69 | 11,397.43 | 10.39 | 17.71 |
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories... that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins or peptides; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products for a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. OPKO Health, Inc. was founded in 2007 and is headquartered in Miami, Florida. Address: 4400 Biscayne Boulevard, Miami, FL, United States, 33137 Read more
Chairman & CEO
Dr. Phillip Frost Ph.D.
Chairman & CEO
Dr. Phillip Frost Ph.D.
Headquarters
Miami, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Opko Health Inc (OPK) stood at $ 2,200 Mln as on 31-Dec-24
The share price of Opko Health Inc (OPK) is $1.43 (NASDAQ) as of 22-Apr-2025 13:38 EDT. Opko Health Inc (OPK) has given a return of -22.23% in the last 3 years.
Opko Health Inc (OPK) has a market capitalisation of $ 1,126 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Opko Health Inc (OPK) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Opko Health Inc (OPK) and enter the required number of quantities and click on buy to purchase the shares of Opko Health Inc (OPK).
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins or peptides; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products for a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. OPKO Health, Inc. was founded in 2007 and is headquartered in Miami, Florida. Address: 4400 Biscayne Boulevard, Miami, FL, United States, 33137
The CEO & director of Dr. Phillip Frost Ph.D.. is Opko Health Inc (OPK), and CFO & Sr. VP is Dr. Phillip Frost Ph.D..
There is no promoter pledging in Opko Health Inc (OPK).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,137
|
|
|
1,132
|
|
|
1,132
|
|
|
1,037
|
| Opko Health Inc (OPK) | Ratios |
|---|---|
|
Return on equity(%)
|
-3.86
|
|
Operating margin(%)
|
5.2
|
|
Net Margin(%)
|
-7.46
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Opko Health Inc (OPK) was $0 Mln.
$0.06
(
